Antifungal activity of tamoxifen: In vitro and in vivo activities and mechanistic characterization

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3337-3346

  Dolan, Kristy ^a   Montgomery, Sara ^a   Buchheit, Bradley ^a   DiDone, Louis ^a   Wellington, Melanie ^a   Krysan, Damian J ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CALMODULIN; CLOMIFENE; FUNGAL PROTEIN; PROTEIN MYO2P; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG ACTIVITY; DRUG STRUCTURE; DRUG TOXICITY; FUNGAL STRAIN; FUNGUS GROWTH; IN VITRO STUDY; IN VIVO STUDY; INVASIVE CANDIDIASIS; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; ANTIFUNGAL AGENTS; CALMODULIN; CANDIDA; CANDIDIASIS; CLOMIPHENE; CRYPTOCOCCUS NEOFORMANS; KIDNEY; MALE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, FLUORESCENCE; TAMOXIFEN;

EID: 67749091065     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01564-08     Document Type: Article

References (52)

1. Afeltra, J., and P. E. Verweij. 2003. Antifungal activity of nonantifungal drugs. Eur. J. Clin. Microbiol. Infect. Dis. 22:397-407.
2. Baral, E., E. Nagy, and I. Berczi. 1995. Modulation of natural killer cell mediated cytoxicity by tamoxifen and estradiol. Cancer 75:591-599.
3. Barns, S. M., D. J. Lane, M. L. Sogin, C. Bibeau, and W. G. Weisburg. 1991. Evolutionary relationships among pathogenic Candida species and relatives. J. Bacteriol. 173:2250-2255.
4. Beggs, W. H. 1993. Anti-candida activity of the anti-cancer drug tamoxifen. Res. Commun. Chem. Pathol. Pharmacol. 80:125-128.
5. Beggs, W. H. 1994. Comparative activities of miconazole and the anticancer drug tamoxifen against Candida albicans. J. Antimicrob. Chemother. 34:186-187.
6. Brockerhoff, S. E., R. C. Stevens, and T. N. Davis. 1994. The unconventional myosin, Myo2p, is a calmodulin target at sites of cell growth in Saccharomyces cerevisiae. J. Cell Biol. 124:215-323.
7. Cyert, M. S. 2001. Genetic analysis of calmodulin and its targets in Saccharomyces cerevisiae. Annu. Rev. Genet. 35:647-672.
8. Edlind, T., L. Smith, K. Henry, S. Katiyar, and J. Nickels. 2002. Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signaling. Mol. Microbiol. 46:257-268.
9. Friedman, Z. Y. 1998. Recent advance in the molecular mechanisms of tamoxifen action. Cancer Investig. 16:391-396.
10. Geiser, J. R., D. van Tuinen, S. E. Brockerhoff, and T. N. Davis. 1991. Can calmodulin function without calcium? Cell 65:949-959.
11. Gelperin, D. M., M. A. White, M. L. Wilkinson, Y. Kon, L. A. Kung, K. J. Wise, N. Lopez-Hoyo, L. Jiang, S. Piccirillo, H. Yu, M. Gerstein, M. E. Dumont, E. M. Phizicky, M. Snyder, and E. J. Grayhack. 2005. Biochemical and genetic analysis of the yeast proteome with a movable ORF collection. Genes Dev. 19:2816-2826.
12. Gray, J. V., J. P. Ogas, Y. Kamada, M. Stone, D. E. Levin, and I. Herskowitz. 1997. A role for the PKC1 MAP kinase pathway of Saccharomyces cerevisiae in bud emergence and identification of an upstream regulator. EMBO J. 16:4924-4937.
13. Kamai, Y., M. Kakuta, T. Shibayama, T. Fukuoka, and S. Kuwahara. 2005. Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice. Antimicrob. Agents Chemother. 49:52-56.
14. Khan, S. Z., C. L. Longland, and F. Michelangeli. 2000. The effects of phenothiazines and other calmodulin antagonists on the sarcoplasmic and endoplasmic reticulum Ca2+ pumps. Biochem. Pharmacol. 15:1797-1806.
15. Krysan, D. J., and L. DiDone. 2008. A high-throughput screening assay for small molecules that disrupt yeast cell integrity. J. Biomol. Screen. 13:657-664.
16. Krysan, D. J., and B. Buchheit. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother./Infect. Dis. Soc. Am. 46th Annu. Meet., abstr. M-2130.
17. Lee, S. Y., and R. E. Klevit. 2000. The whole is not the simple sum of its parts in calmodulin from S. cerevisiae. Biochemistry 39:4225-4230.
18. Lens, M. B., T. Reiman, and A. F. Husain. 2003. Use of tamoxifen in the treatment of malignant melanoma. Cancer 98:355-361.
19. Levin, D. E., and E. Bartlett-Heubusch. 1992. Mutants in the S. cerevisiae PKC1 gene display a cell cycle-specific osmotic stability defect. J. Cell Biol. 116:1221-1229.
20. 2+-dependent binding of tamoxifen to calmodulin isolated from bovine brain. Cancer Res. 50:2753-2758.
21. Luesch, H. 2006. Towards a high-throughput characterization of small molecule mechanisms of action. Mol. Biosys. 2:609-620.
22. Luesch, H., T. Y. H. Wu, P. Ren, N. S. Gray, P. G. Schulz, and F. Supek. 2005. A genome-wide overexpression screen in yeast for small-molecule target identification. Chem. Biol. 12:55-63.
23. Markovich, S., A. Yekutiel, I. Shalit, Y. Shadkohan, and N. Y. Osherov. 2004. Genomic approach to identification of mutations affecting caspofungin sensitivity in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 48:3871-3876.
24. Molina, M., H. Martin, M. Sanchez, and C. Nombela. 1998. MAP kinasemediated signal transduction pathways. Methods Microbiol. 26:259-281.
25. Morello, K. C., G. T. Wurz, and M. W. DeGregorio. 2003. Pharmacokinetics of estrogen receptor modulator. Clin. Pharmacokinet. 42:361-372.
26. Muend, S., and R. Rao. 2008. Fungicidal activity of amiodarone is tightly coupled to calcium influx. FEMS Yeast Res. 8:425-431.
27. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
28. Nilsson, U. W., J. A. Jonsson, and C. Dabrosin. 2009. Tamoxifen decreases extracellular TGF-beta1 secreted by breast cancer cells-a posttranslational regulation involving matrix metalloproteinase activity. Exp. Cell Res. 315: 1-9.
29. Nucci, M., and J. R. Perfect. 2008. When primary antifungal therapy fails. Clin. Infect. Dis. 46:1426-1433.
30. O'Brian, C. A., N. E. Ward, and B. W. Anderson. 1988. Role of specific interactions between protein kinase C and triphenylethylenes in inhibition of the enzyme. J. Natl. Cancer Inst. 80:1628-1633.
31. Ohya, Y., and D. Botstein. 1994. Diverse essential functions revealed by complimentary yeast calmodulin mutants. Science 263:963-966.
32. Ohya, Y., and D. Botstein. 1994. Structure-based systematic isolation of conditional-lethal mutations in the single yeast calmodulin gene. Genetics 138:1041-1054.
33. Onyewu, C., J. R. Blankenship, M. Del Poeta, and J. Heitman. 2003. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob. Agents Chemother. 47:956-964.
34. Parsons, A. B., A. Lopez, T. E. Givini, D. E. Williams, C. A. Gray, J. Porter, G. Chua, R. Sopko, R. L. Brost, C.-H. Ho, J. Wang, T. Ketela, C. Brenner, J. A. Brill, G. E. Fernandez, T. C. Lorenz, G. S. Payne, S. Ishihara, Y. Ohya, B. Andrews, and C. Boone. 2006. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 126:611-625.
35. Patterson, T. F. 2005. Advances in the management of invasive mycoses. Lancet 336:1013-1025.
36. Perez, E. A., D. R. Gandara, M. J. Edelman, R. O'Donnell, I. J. Lauder, and M. DeGregorio. 2003. Phase 1 trial of high dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Cancer Investig. 21:1-6.
37. Pringle, J. R., R. A. Preston, A. E. M. Adams, T. Stearns, D. G. Drubin, B. K. Haaver, and E. W. Jones. 1989. Fluorescence microscopy methods for yeast. Methods Cell Biol. 21:357-435.
38. Robins, H. T., M. Won, W. F. Seiferheld, C. J. Schultz, A. K. Choucair, D. G. Brachman, W. F. Demas, and M. P. Mehta. 2006. Phase 2 trial of radiation plus high dose tamoxifen for glioblastoma multiforme: RTG protocol BR-0021. Neuro-oncology 8:47-52.
39. Robinson, S. P., S. M. Langan-Fahey, D. A. Johnson, and V. C. Jordan. 1991. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to breast cancer patients. Drug Metab. Disp. 19:36-43.
40. Rowlands, M. G., J. Budworth, M. Jarman, I. R. Hardcastle, R. McGague, and A. Gersher. 1995. Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues. Biochem. Pharmacol. 50:723-726.
41. Saville, S. P., A. L. Lazzell, A. P. Bryant, A. Fretzen, A. Monreal, E. O. Solberg, C. Monteagudo, J. L. Lopez-Ribot, and G. T. Milne. 2006. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob. Agents Chemother. 50:3312-3316.
42. Toenjes, K. A., S. M. Munsee, A. S. Ibrahim, R. Jeffery, J. E. Edwards, and D. I. Johnson. 2005. Small molecule inhibitors of the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans. Antimicrob. Agents Chemother. 49:963-972.
43. Wagner, E. M., S. J. Gallagher, S. Reddy, and W. Mitzner. 2003. Effects of tamoxifen on ischemia-induced angiogenesis in the mouse lung. Angiogenesis 6:65-71.
44. Walsh, T. J., M. A. Vivani, E. Arathooy, C. Chiou, M. Ghannoum, A. H. Groll, and F. C. Odds. 2000. New targets and delivery systems for antifungal therapy. Med. Mycol. 38:335-347.
45. Wilson, L. C., C. M. Reyes, M. Stolpman, J. Speckman, K. Allen, and J. Beney. 2002. The direct cost of systemic fungal infections. Value Health 5:26-34.
46. Wiseman, H., M. Cannon, and H. R. V. Arnstein. 1989. Observation and significance of growth inhibition of Saccharomyces cerevisiae (A224A) by the anti-oestrogen drug tamoxifen. Biochem. Soc. Trans. 17:1038-1039.
47. Wiseman, H., M. Cannon, H. R. V. Arnstein, and B. Halliwell. 1993. Enhancement by tamoxifen of the membrane antioxidant action of the yeast membrane sterol ergosterol: relevance to the antiyeast and anticancer action of tamoxifen. Biochim. Biophys. Acta 1181:201-206.
48. Wiseman, H., P. Quinn, and B. Halliwell. 1993. Tamoxifen and related compounds decrease membrane fluidity in liposomes. Mechanism for the antioxidant action of tamoxifen and relevance to cardioprotective actions? FEBS Lett. 330:53-56.
49. Woo, M., K. Lee, and L. Song. 2003. MYO2 is not essential for viability but is required for polarized growth and dimorphic switches in Candida albicans. FEMS Microbiol. Lett. 218:195-202.
50. Yoshida, S., Y. Ohya, M. Goebl, A. Nakano, and Y. Anraku. 1994. A novel gene STT4 encodes a phosphatidylinositol 4-kinase in the PKC1 protein kinase pathway of Saccharomyces cerevisiae. J. Biol. Chem. 269:1166-1172.
51. Zhang, Y.-Q., and R. Rao. 2007. Global disruption of cell cycle progression and nutrient response by the antifungal agent amiodarone. J. Biol. Chem. 282:37844-37853.
52. Zhu, H., M. Biglin, R. Bangham, D. Hall, A. Casamayor, P. Bertone, N. Lan, R. Jensen, S. Bidlingmaier, T. Houfek, T. Mitchell, P. Miller, M. Gertstein, and M. Snyder. 2001. Global analysis of proteins activities using proteome chips. Science 293:2101-2105.